Home › Trials › NCT05887011

Examining treatment patterns and outcomes for advanced lung cancer in Russia

National Multicentre Non-interventional Study to Assess CRT Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Observational AstraZeneca · NCT05887011

This study looks at how patients with advanced lung cancer in Russia are treated and what their outcomes are after receiving chemoradiation therapy.

Quick facts

Study typeObservational
Enrollment2000 (estimated)
Ages18 Years and up
SexAll
SponsorAstraZeneca Industry-sponsored
Drugs / interventionsdurvalumab
Locations41 sites (Arkhangelsk and 40 other locations)
Trial IDNCT05887011 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the routine diagnostic and treatment practices for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) and limited-stage small cell lung cancer (SCLC) across 50 major oncology centers in Russia. Over a two-year period, data will be collected from the medical records of approximately 2000 patients receiving chemoradiation therapy (CRT). The study will focus on demographic and clinical characteristics, treatment approaches, and outcomes at the end of CRT, while adhering to local regulatory requirements for adverse event reporting. The study will not collect data on specific post-CRT treatments.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with unresectable locally advanced NSCLC or limited-stage SCLC who are currently undergoing radiotherapy as part of their treatment.

Not a fit: Patients who have participated in another clinical study with an investigational product in the last three months or those without written informed consent will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of current treatment practices for advanced lung cancer, potentially leading to improved patient outcomes.

How similar studies have performed: While this study focuses on routine practices in Russia, similar observational studies in other regions have provided valuable data on treatment outcomes, suggesting potential for meaningful insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥ 18 years old
2. Provision of written informed consent
3. Patient received at least one RT dose under prescribed CRT (concurrent or sequential) for definitive treatment of locally advanced NSCLC (stage II-III, unresectable or inoperable NSCLC, including locoregional recurrence and patient's refusal to undergo surgery) or LS-SCLC based on local MDT decision
4. Patient is currently undergoing RT (preferably no more than 10 doses)

Exclusion Criteria:

1. Participation in another clinical study with an investigational product during the last 3 months
2. Confirmation that the subject was already included in this study before
3. Absence of written informed consent form
4. Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database.

Where this trial is running

Arkhangelsk and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Unresectable /Inoperable Locally Advanced NSCLC and Locally Advanced LS-SCLC
Last reviewed 2026-06-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.